Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Virus-Cell Interactions

An Equine Infectious Anemia Virus Variant Superinfects Cells through Novel Receptor Interactions

Melinda A. Brindley, Baoshan Zhang, Ronald C. Montelaro, Wendy Maury
Melinda A. Brindley
1Department of Microbiology, University of Iowa, Iowa City, Iowa 52242
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Baoshan Zhang
2Center for Vaccine Research, Department of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15261
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald C. Montelaro
2Center for Vaccine Research, Department of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15261
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy Maury
1Department of Microbiology, University of Iowa, Iowa City, Iowa 52242
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wendy-maury@uiowa.edu
DOI: 10.1128/JVI.01142-08
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    ELR1 remains on the surface of EIAV-infected cells. ED cells and eUVECs (A) and chronically EIAV-infected cells (B) were immunostained for surface expression of ELR1 using rabbit polyclonal antisera against the ectodomain of ELR1. EIAV-infected populations were greater than 90% positive for EIAV antigens. Allophycocyanin-conjugated goat-anti-rabbit was used as a secondary antibody. Flow cytometry of live, stained cells was used to determine the percentage of the population that was positive for ELR1 (solid area). Secondary antisera alone (black line) as well as rabbit control sera (gray line) were used as negative controls. A representative flow experiment is shown. The experiments were performed three independent times.

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    EIAV SU blocks entry of wild-type strains of EIAV. ED cells (A) or eUVECs (B) were incubated with increasing amounts of 293T cell supernatants that had been either transfected with an empty vector or a codon-optimized EIAVSP19 SU expression vector. The cells were subsequently infected with EIAVMA-1 or EIAVvMA-1c or transduced with VSV-G-pseudotyped EIAV particles that express β-galactosidase. Cells were evaluated for infection or transduction at 40 h. Shown is the ratio of the number of infected or transduced cells in the presence of supernatant divided by the number of infected or transduced cells when no supernatant was added. Data represent the means and standard errors of the means from three separate experiments performed in triplicate. *, P < 0.05; **, P < 0.001.

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    EIAVvMA-1c can enter ED cells in an ELR1-independent manner. ED cells (A) or eUVECs (B) were incubated with preimmune serum or polyclonal anti-ELR1 antiserum at 4°C for 30 min. The cells were subsequently infected with EIAVMA-1 or EIAVvMA-1c or transduced with VSV-G-pseudotyped EIAV particles. Cells were stained 40 h after infection. Shown is the ratio of the number of infected or transduced cells in the presence of antiserum divided by the number of infected or transduced cells when no antiserum was added. Data represent the means and standard errors of the means from three separate experiments performed in triplicate. *, P < 0.05; **, P < 0.001.

  • FIG. 4.
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    siRNA knockdown of ELR1 decreases EIAV entry into ED cells. ED cells were transfected with a control siRNA or ELR1 siRNA. Forty-eight hours after transfection, cells were either harvested for immunoblotting or used in infection/transduction studies. Cell lysates were immunoblotted for ELR1 and a tubulin loading control (A). Cells were stained for EIAV antigens or β-Gal activity at 40 h after infection (88 h after transfection) (B). Data represent the means and standard errors of the means from three separate experiments performed in triplicate. *, P < 0.05.

  • FIG. 5.
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    EIAVvMA-1c retains the ability to interact with ELR1, and this interaction inhibits entry. EIAVMA-1 or EIAVvMA-1c virions and VSV-G-pseudotyped EIAV particles (MOI, 0.005) were incubated with the soluble ectodomain of ELR1 for 30 min at 4°C. The viruses were evaluated for ED cell infection. Cells were stained 40 h after infection. Shown is the ratio of the number of infected or transduced cells in the presence of ELR1 ectodomain divided by the number of infected or transduced cells when no ectodomain was added. Data represent the means and standard errors of the means from three separate experiments performed in triplicate.

  • FIG. 6.
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    Interference with ELR1-EIAV interactions does not inhibit EIAVvMA-1c superinfection-dependent cell killing. ED cells were treated with inhibitors of ELR1-dependent entry at concentrations previously shown to inhibit 90% of EIAVMA-1 infectivity. The treated cells were infected with EIAVvMA-1c, and 4 days after infection the cells were assayed for viability. Data represent the means and standard errors of the means from three separate experiments performed in triplicate. Anti-EIAV, 1:60 dilution of equine anti-EIAV serum 2085; control sups, 100 μl of supernatant from 293T cells; WT EIAV SU sups, 100 μl of supernatant from codon-optimized SU-transfected 293T cells; normal rabbit serum, 1:60 dilution of normal rabbit serum; anti-ELR1, 1:60 of rabbit anti-ELR1 antiserum; NH4Cl, 30 mM ammonium chloride; CPZ, 20 μg/ml of chlorpromazine. **, P < 0.001.

  • FIG. 7.
    • Open in new tab
    • Download powerpoint
    FIG. 7.

    EIAVvMA-1c has similar binding kinetics for ELR1 as EIAVMA-1. EIAVMA-1 or EIAVvMA-1c binding kinetics were evaluated in ED cells (A), in ED cells in the presence of preimmune serum or anti-ELR1 antiserum (diluted 1:60) (B), and eUVECs (C). Virus particles were added to cells and then removed at the time points indicated. Cells were stained 40 h after infection and compared to the number of infected cells when particles were not removed. Data represent the means and standard errors of the means from three separate experiments performed in triplicate. *, P < 0.05.

PreviousNext
Back to top
Download PDF
Citation Tools
An Equine Infectious Anemia Virus Variant Superinfects Cells through Novel Receptor Interactions
Melinda A. Brindley, Baoshan Zhang, Ronald C. Montelaro, Wendy Maury
Journal of Virology Sep 2008, 82 (19) 9425-9432; DOI: 10.1128/JVI.01142-08

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
An Equine Infectious Anemia Virus Variant Superinfects Cells through Novel Receptor Interactions
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
An Equine Infectious Anemia Virus Variant Superinfects Cells through Novel Receptor Interactions
Melinda A. Brindley, Baoshan Zhang, Ronald C. Montelaro, Wendy Maury
Journal of Virology Sep 2008, 82 (19) 9425-9432; DOI: 10.1128/JVI.01142-08
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Dermis
Infectious Anemia Virus, Equine
Receptors, Virus

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514